{Reference Type}: Review
{Title}: Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?
{Author}: Le Roux C;Mondoh A;
{Journal}: Expert Opin Pharmacother
{Volume}: 25
{Issue}: 2
{Year}: 2024 Feb 1
{Factor}: 4.103
{DOI}: 10.1080/14656566.2024.2311731
{Abstract}: <B>UNASSIGNED: </B>Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations.<BR><B>UNASSIGNED: </B>Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulous analysis of phase 2 and phase 3 data positions retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide in order of effectiveness. While showcasing their efficacy and safety, the review acknowledges the ongoing phase 3 studies, highlighting the need for further exploration of contraindications, dosage, and potential adverse effects to inform personalized treatment decisions.<BR><B>UNASSIGNED: </B>The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.